<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bismuth subsalicylate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bismuth subsalicylate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Bismuth subsalicylate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="101045" href="/d/html/101045.html" rel="external">see "Bismuth subsalicylate: Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="101046" href="/d/html/101046.html" rel="external">see "Bismuth subsalicylate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F27758285"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Bismatrol Maximum Strength [OTC] [DSC];</li>
<li>Bismatrol [OTC] [DSC];</li>
<li>Diotame InstyDose [OTC];</li>
<li>Diotame [OTC] [DSC];</li>
<li>FT Stomach Relief [OTC];</li>
<li>Geri-Pectate [OTC] [DSC];</li>
<li>GoodSense Stomach Relief [OTC];</li>
<li>Kaopectate [OTC];</li>
<li>Peptic Relief [OTC] [DSC];</li>
<li>Pepto-Bismol To-Go [OTC];</li>
<li>Pepto-Bismol [OTC];</li>
<li>Pink Bismuth [OTC];</li>
<li>Stomach Relief Extra Strength [OTC];</li>
<li>Stomach Relief Plus [OTC];</li>
<li>Stomach Relief [OTC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F27758290"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidiarrheal</li></ul></div>
<div class="block doa drugH1Div" id="F27758326"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2dfca340-d571-4dc0-9e72-61ab988e54f0">Diarrhea/dyspepsia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diarrhea/dyspepsia:</b>
<b>Oral:</b> ~524 mg every 30 to 60 minutes or 1,050 mg every 60 minutes as needed for up to 2 days (maximum: ~4,200 mg/24 hours).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b8d4809-3f39-4624-a159-df262570daf3">
<i>Helicobacter pylori</i> eradication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Helicobacter pylori</i> eradication (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">American College of Gastroenterology guidelines (Chey 2007; Chey 2017): <i>Bismuth quadruple therapy: </i>
<b>Oral:</b> 300 mg 4 times daily in combination with tetracycline 500 mg 4 times daily, either metronidazole 500 mg 3 or 4 times daily or 250 mg 4 times daily, and standard-dose proton pump inhibitor twice daily; continue regimen for 10 to 14 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e2d163ff-ec5c-4f07-9c22-2e0145c56d00">Travelers' diarrhea, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Travelers' diarrhea, prophylaxis (off-label use):</b>
<b>Oral:</b> ~524 mg 4 times daily with meals and at bedtime during period of risk (ACG [Riddle 2016]; CDC 2020). <b>Note:</b> Safety has not been established for periods &gt;3 weeks (CDC 2020); some experts do not recommend use for trips exceeding 2 weeks in duration (ACG [Riddle 2016]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8371a59a-1dc4-47ca-aaef-c1e699b5bc49">Travelers' diarrhea, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Travelers' diarrhea, treatment:</b>
<b>Oral:</b> ~524 mg every 30 to 60 minutes or 1,050 mg every 60 minutes as needed (maximum: ~4,200 mg/24 hours) (ACG [Riddle 2016]; manufacturer's labeling).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991129"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥50 mL/minute: No dosage adjustment necessary (expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;50 mL/minute: No dosage adjustment necessary; however, use with caution as salicylates can potentially worsen kidney function in patients dependent on prostaglandins to maintain glomerular filtration rate, salicylate toxicity can occur at lower doses in patients with kidney insufficiency compared to those with normal kidney function, and bismuth can accumulate with long-term use in patients with severe kidney dysfunction. Use the lowest effective dose and limit durations of therapy when clinically feasible (Bradley 1989; Gladziwa 1994; Khim 2017; Palmer 2020; Pelepenko 2022; expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>): </b>Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematological malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (Bilbao-Meseguer 2018; Udy 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">No dosage adjustment necessary (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): </b>Salicylate is unlikely to be significantly dialyzable at therapeutic serum concentrations since highly protein bound; however, at supratherapeutic concentrations, protein binding is saturated and salicylates are readily dialyzable (Palmer 2020). Bismuth undergoes limited dialytic clearance (Khim 2017; Pelepenko 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">No dosage adjustment necessary; however, use should generally be avoided as salicylate toxicity can occur at lower doses in patients with kidney insufficiency compared to those with normal kidney function, and bismuth can accumulate with long-term use. If necessary, use the lowest effective dose for the shortest duration of time (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> No dosage adjustment necessary; however, use should generally be avoided as salicylate toxicity can occur at lower doses in patients with kidney insufficiency compared to those with normal kidney function, and bismuth can accumulate with long-term use. If necessary, use the lowest effective dose for the shortest duration of time (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary; however, use should generally be avoided as salicylates can potentially worsen acute kidney injury (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT: </b>No dosage adjustment necessary; however, use should generally be avoided as salicylates can potentially worsen acute kidney injury (expert opinion).</p></div>
<div class="block doha drugH1Div" id="F50988458"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F27758327"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F27758325"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="101045" href="/d/html/101045.html" rel="external">see "Bismuth subsalicylate: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Multiple concentrations of oral liquid formulations exist; close attention must be paid to the concentration when ordering or administering. Children and adolescents who have or are recovering from chicken pox or flu-like symptoms should not use bismuth subsalicylate due to the association with Reye syndrome. Refer to product-specific labeling for approved pediatric ages. Dosing presented as mg of bismuth subsalicylate.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b245236b-1cd4-4d6d-8a7f-2a20bb444f56">Diarrhea, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diarrhea, chronic</b> (Gryboski 1985; Gryboski 1990): Limited data available: Oral liquid:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months: Oral: 44 mg every 4 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;2 years: Oral: 44 mg every 4 hours <b>or</b> 87 mg every 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to &lt;3 years: Oral: 87 mg every 4 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 3 to &lt;4 years: Oral: 87 mg every 4 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 4 to 6 years: Oral: 175 mg every 4 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Dosing based on 2 studies; the first was a prospective, double-blind, placebo-controlled clinical trial of 29 infants and children with chronic diarrhea (&gt;6 weeks); after 7 days of bismuth therapy, patients in the treatment group (n=15, age 2 to 30 months) gained significantly more weight and had significantly improved stool characteristics (consistency/frequency) compared to placebo; to prevent recurrence of symptoms, the authors also suggested tapering the medication at the end of therapy (Gryboski 1985). A second study compared bismuth subsalicylate with cholestyramine; patients were treated with bismuth (n=19) for 7 days; bismuth was found to be as effective as cholestyramine in binding of bile acids and at decreasing stool frequency (Gryboski 1990).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5e0ba50c-6f83-4010-828c-ff425d351382">Diarrhea, dyspepsia, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diarrhea, dyspepsia, acute (gas, upset stomach, indigestion, heartburn, nausea):</b> OTC labeling:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 524 mg every 30 to 60 minutes <b>or</b> 1,050 mg every 60 minutes as needed for up to 2 days. Maximum daily dose: 4,200 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b8d4809-3f39-4624-a159-df262570daf3">
<i>Helicobacter pylori</i> eradication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Helicobacter pylori</b></i>
<b> eradication:</b> Limited data available: <b>Note: </b>Use as part of an appropriate combination regimen; usual duration of therapy is 14 days (NASPGHAN/ESPGHAN [Jones 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents (NASPGHAN/ESPGHAN [Jones 2017]):</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;10 years: Oral: 262 mg 4 times daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥10 years: Oral: 524 mg 4 times daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3dfeda8b-60ae-4122-bdd8-95de1915ba6c">Travelers' diarrhea</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Travelers' diarrhea</b> (Gal 2007; Leung 2019; manufacturer's labeling): Limited data available in children &lt;12 years:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 3 to &lt;6 years: Oral: 87 mg every 30 to 60 minutes as needed; do not exceed 8 doses per 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to &lt;9 years: Oral: 175 mg every 30 to 60 minutes as needed; do not exceed 8 doses per 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 9 to &lt;12 years: Oral: 262 mg every 30 to 60 minutes as needed; do not exceed 8 doses per 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 524 mg every 30 to 60 minutes <b>or</b> 1,050 mg every 60 minutes as needed; maximum dose: 4,200 mg per 24 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51073579"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51073580"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F27758303"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">There are no adverse reactions listed in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Esophagitis (acute esophageal necrosis) (Abed 2014), melena (Bierer 1990), melanoglossia (Bierer 1990), staining of tooth (Borbinha 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (More 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Encephalopathy (Borbinha 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (Castelli 2006)</p></div>
<div class="block coi drugH1Div" id="F27758300"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">OTC labeling: When used for self-medication, do not use if you are allergic to salicylates (including aspirin) or are taking other salicylates; have an ulcer, bleeding problem or bloody/black stool.</p></div>
<div class="block war drugH1Div" id="F27758301"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxicity: Bismuth products may be neurotoxic with very large doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage forms</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diagnostic GI procedures: Bismuth absorbs x-rays and may interfere with diagnostic procedures of GI tract.</p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): Pediatric patients who have or are recovering from chickenpox or flu-like symptoms should not use subsalicylate. Changes in behavior (along with nausea and vomiting) may be an early sign of Reye syndrome; patients should be instructed to contact their health care provider if these occur. A temporary harmless darkening of the stool and/or tongue may occur with use. Contact a health care provider before use if fever or mucus in the stool occurs. Discontinue use and contact health care provider if any of the following occur: diarrhea lasts &gt;2 days, diarrhea with a fever, symptoms get worse, hearing loss, or ringing in the ears.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878682"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Do not use aspirin-containing products in children and adolescents who have or who are recovering from chickenpox or flu symptoms (due to the association with Reye syndrome); when using aspirin, changes in behavior (along with nausea and vomiting) may be an early sign of Reye syndrome; instruct patients and caregivers to contact their health care provider if these symptoms occur.</p></div>
<div class="block foc drugH1Div" id="F27758340"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bismatrol Maximum Strength: 525 mg/15 mL (236 mL [DSC]) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium; wintergreen flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diotame InstyDose: 262 mg/15 mL (30 mL) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium, salicylic acid]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Stomach Relief: 525 mg/30 mL (236 mL) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium, salicylic acid]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Geri-Pectate: 262 mg/15 mL (355 mL [DSC]) [contains fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense Stomach Relief: 525 mg/30 mL (236 mL) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium, salicylic acid]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense Stomach Relief: 1050 mg/30 mL (236 mL) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kaopectate: 262 mg/15 mL (325 mL) [contains fd&amp;c red #40 (allura red ac dye); peppermint flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pepto-Bismol: 262 mg/15 mL (118 mL) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium; original flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pink Bismuth: 262 mg/15 mL (473 mL [DSC]) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Stomach Relief: 525 mg/15 mL (237 mL) [contains d&amp;c red #22 (eosine), saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Stomach Relief: 525 mg/30 mL (237 mL) [alcohol free, sugar free; contains benzoic acid, d&amp;c red #22 (eosine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Stomach Relief Extra Strength: 525 mg/15 mL (237 mL) [alcohol free, sugar free; contains benzoic acid, d&amp;c red #22 (eosine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Stomach Relief Plus: 525 mg/15 mL (240 mL, 480 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 525 mg/30 mL (30 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral, as subsalicylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bismatrol: 262 mg/15 mL (236 mL [DSC]) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium; wintergreen flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Geri-Pectate: 262 mg/15 mL (355 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pepto-Bismol: 262 mg/15 mL (473 mL) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pink Bismuth: 262 mg/15 mL (236 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pink Bismuth: 262 mg/15 mL (237 mL [DSC]) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Stomach Relief: 527 mg/30 mL (240 mL, 480 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Stomach Relief: 262 mg [contains saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Stomach Relief: 262 mg [contains aspartame]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 262 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral, as subsalicylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bismatrol: 262 mg [DSC] [contains saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diotame: 262 mg [DSC] [contains aspartame]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Peptic Relief: 262 mg [DSC] [contains saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pepto-Bismol To-Go: 262 mg [sugar free; contains fd&amp;c red #40(allura red ac)aluminum lake, saccharin sodium; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 262 mg</p></div>
<div class="block geq drugH1Div" id="F27758288"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F27758342"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Bismuth Subsalicylate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">262 mg (per each): $0.06 - $0.09</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F27758330"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Shake liquids well prior to use. Chew tablets thoroughly or allow to dissolve in the mouth before swallowing. Nonchewable tablets should be swallowed whole with a full glass of water.</p></div>
<div class="block admp drugH1Div" id="F52614045"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Liquid: Shake well before using.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets, chewable: Chew or allow to dissolve in mouth before swallowing.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets, nonchewable caplets: Swallow whole with a full glass of water.</p></div>
<div class="block use drugH1Div" id="F27758294"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diarrhea:</b> Relief of diarrhea.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dyspepsia:</b> Relief of upset stomach, including belching, fullness, gas, indigestion, heartburn, and nausea.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Travelers’ diarrhea, treatment:</b> Relief of travelers’ diarrhea.</p></div>
<div class="block off-label drugH1Div" id="F27758295"><span class="drugH1">Use: Off-Label: Adult</span><p>Helicobacter pylori eradication; Travelers' diarrhea, prophylaxis</p></div>
<div class="block mst drugH1Div" id="F27758283"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Kaopectate may be confused with Kayexalate</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Salicylates, when used in pediatric patients &lt;18 years of age with suspicion of viral illness (influenza, chickenpox), are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be used with caution due to risk of Reye syndrome (weak recommendation; very low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Canadian formulation of Kaopectate does not contain bismuth; the active ingredient in the Canadian formulation is attapulgite.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F27758310"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F27758307"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Salicylates may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Salicylates may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ammonium Chloride: May increase the serum concentration of Salicylates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Salicylates may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Salicylates may diminish the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Salicylates may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzbromarone: Salicylates may diminish the therapeutic effect of Benzbromarone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bismuth Subcitrate: Bismuth-Containing Compounds may enhance the neurotoxic effect of Bismuth Subcitrate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.  Management: Avoid these combinations when possible.Dichlorphenamide use with high-dose aspirin as contraindicated. If another combination is used, monitor patients closely for adverse effects. Tachypnea, anorexia, lethargy, and coma have been reported.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexketoprofen: Salicylates may enhance the adverse/toxic effect of Dexketoprofen. Dexketoprofen may diminish the therapeutic effect of Salicylates. Salicylates may decrease the serum concentration of Dexketoprofen.  Management: The use of high-dose salicylates (3 g/day or more in adults) together with dexketoprofen is inadvisable. Consider administering dexketoprofen 30-120 min after or at least 8 hrs before cardioprotective doses of aspirin to minimize any possible interaction.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ginkgo Biloba: May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Salicylates may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccine (Live/Attenuated): May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Salicylates may diminish the therapeutic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.  Management: Consider avoiding coadministration of methotrexate and salicylates. If coadministration cannot be avoided, monitor for increased toxic effects of methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Management: Nonselective NSAIDs may reduce aspirin's cardioprotective effects. Administer ibuprofen 30-120 minutes after immediate-release aspirin, 2 to 4 hours after extended-release aspirin, or 8 hours before aspirin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Salicylates. Specifically, the risk of gastrointestinal (GI) toxicity is increased. Management: Coadministration of salicylates and topical NSAIDs is not recommended. If salicylates and topical NSAIDs are coadministered, ensure the benefits outweigh the risks and monitor for increased NSAID toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Phosphate: May increase the serum concentration of Salicylates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PRALAtrexate: Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern.  Management: Consider avoiding concomitant use of salicylates and pralatrexate. If coadministered, monitor for increased pralatrexate adverse effects. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: Salicylates may diminish the therapeutic effect of Probenecid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the anticoagulant effect of other Salicylates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfinpyrazone: Salicylates may decrease the serum concentration of Sulfinpyrazone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: Bismuth Subsalicylate may decrease the serum concentration of Tetracyclines.  Management: Consider dosing tetracyclines 2 hours before or 6 hours after bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: Salicylates may increase the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Varicella Virus-Containing Vaccines: Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Specifically, the risk for Reye's syndrome may increase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists.  Management: Avoid as needed use of salicylates in patients taking vitamin K antagonists. Aspirin (80 to 325 mg/day) may be used with warfarin for prevention of cardiovascular events. If coadministering salicylates and vitamin K antagonists, monitor for bledding.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F27758298"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Bismuth subsalicylate is converted to bismuth and salicylic acid in the GI tract. Following oral administration, salicylates cross the placenta. Very little bismuth is systemically absorbed from this preparation (Bierer 1990; Lione 1988).</p>
<p style="text-indent:0em;margin-top:2em;">Following ingestion of bismuth subsalicylate, plasma salicylate concentrations may be comparable to those following ingestion of aspirin (Bierer 1990; Lione 1988). Refer to the aspirin monograph for additional information related to salicylates and pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Bismuth subsalicylate should not be used in pregnant patients for the treatment of dyspepsia or acute diarrhea (Body 2016) and current guidelines do not recommend use for the treatment or prevention of travelers' diarrhea in pregnancy (CDC 2020).</p></div>
<div class="block brc drugH1Div" id="F27758299"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Salicylates enter breast milk (Bar-Oz 2003). Following ingestion of bismuth subsalicylate, plasma salicylate concentrations may be comparable to those following ingestion of aspirin (Bierer 1990). Refer to the aspirin monograph for additional information related to salicylates and breastfeeding.</p>
<p style="text-indent:-2em;margin-left:2em;">It is not known if bismuth is present in breast milk; however, absorption is limited following oral administration of this preparation at usual doses (Bierer 1990).</p>
<p style="text-indent:-2em;margin-left:2em;">A case report describes bowel obstruction in a breastfed infant whose mother applied a bismuth-containing ointment to her nipples prior to breastfeeding (Ingestion of bismuth-containing 1974).</p></div>
<div class="block dic drugH1Div" id="F27758329"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Drink plenty of fluids to help prevent dehydration caused by diarrhea. Some products may contain phenylalanine, potassium, and/or sodium.</p></div>
<div class="block pha drugH1Div" id="F27758316"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Bismuth subsalicylate exhibits both antisecretory and antimicrobial action. This agent may provide some anti-inflammatory action as well. The salicylate moiety provides antisecretory effect and the bismuth exhibits antimicrobial directly against bacterial and viral gastrointestinal pathogens.</p></div>
<div class="block phk drugH1Div" id="F27758318"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Bismuth: &lt;1%; Subsalicylate: &gt;80%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Salicylate: V<sub>d</sub>: 170 mL/kg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding, plasma: Bismuth and salicylate: &gt;90%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Bismuth subsalicylate is converted to bismuth and salicylic acid in the GI tract.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Terminal: Bismuth: 21 to 72 days; Salicylate: 2 to 5 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Bismuth: Urine and biliary; Salicylate: Urine (10% excreted unchanged)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F27758344"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bismutol | Pepto bismol</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Bismed | Pepto care | Peptocid | Pink bismol</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Pepto bismol | Pepto-zil</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Bisbacter | Gastroaliv</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Pepto bismol | Xi xin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bis-bacter | Bisbacter | Bislakso | Bismucar | Pepto bismol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Jatrox s</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Jatrox s</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Bismutal | Bismutal forte | Pink bismuth</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Bismutol | Pepto bismol | Peptocid</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Almus Pepti Calm | Boots pepti calm | Pepto bismol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Pepto bismol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Pepbilon</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Pepto bismol</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Kalbeten | Peptolite</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Kaopectate</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Bismatrol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bismed | Bismuth | Daclafin | Itamol | Mut p | Neuzil plus | Pepto bismol | Siparox | Subsalicylate bismuth iqfa | Subsalicylate bismuth ultra | Vitofolia</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Pepto bismol</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Acidplus | Argol | Biobismuto | Bisbacter | Bismoclin | Bismolud | Bismosan | Bismualiv | Bismucar | Bismufresh | Bismutol | Labutol | Nulacin | Peptogastrin | Peptogastrin forte | Subsalicilato de Bismuto | Ulcimet</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Akso-D | Bismol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Bismatrol | Diotame | Diotame instydose | Geri Pectate | K-Pek | Kao-Tin | Kaopectate | Kola pectin ds | Maalox total relief | Medi first Pep T Med | Pink bismuth</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Gastrodine</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Gastro-bismol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Bizmopeptol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Assure</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Bismutol</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bismutol | Pepto bismol | Peptogel</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Intungwa</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26157851">
<a name="26157851"></a>Abed J, Mankal P, Judeh H, Kim S. Acute esophageal necrosis: a case of black esophagus associated with bismuth subsalicylate ingestion. <i>ACG Case Rep J</i>. 2014;1(3):131-133. doi:10.14309/crj.2014.27<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/26157851/pubmed" id="26157851" target="_blank">26157851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14583068">
<a name="14583068"></a>Bar-Oz B, Bulkowstein M, Benyamini L, et al. Use of antibiotic and analgesic drugs during lactation. <i>Drug Saf</i>. 2003;26(13):925-935.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/14583068/pubmed" id="14583068" target="_blank">14583068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2406853">
<a name="2406853"></a>Bierer DW. Bismuth subsalicylate: history, chemistry, and safety. <i>Rev Infect Dis</i>. 1990;12(suppl 1):S3-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/2406853/pubmed" id="2406853" target="_blank">2406853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aurohealth.1">
<a name="Aurohealth.1"></a>Bismuth Subsalicylate Maximum Strength Stomach Relief Liquid [prescribing information]. Lawrenceville, NJ: Aurohealth LC; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27261898">
<a name="27261898"></a>Body C, Christie JA. Gastrointestinal diseases in pregnancy: nausea, vomiting, hyperemesis gravidarum, gastroesophageal reflux disease, constipation, and diarrhea. <i>Gastroenterol Clin North Am</i>. 2016;45(2):267‐283. doi:10.1016/j.gtc.2016.02.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/27261898/pubmed" id="27261898" target="_blank">27261898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31464594">
<a name="31464594"></a>Borbinha C, Serrazina F, Salavisa M, Viana-Baptista M. Bismuth encephalopathy- a rare complication of long-standing use of bismuth subsalicylate. <i>BMC Neurol</i>. 2019;19(1):212. doi:10.1186/s12883-019-1437-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/31464594/pubmed" id="31464594" target="_blank">31464594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2693474">
<a name="2693474"></a>Bradley B, Singleton M, Lin Wan Po A. Bismuth toxicity--a reassessment. <i>J Clin Pharm Ther</i>. 1989;14(6):423-441. doi:10.1111/j.1365-2710.1989.tb00268.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/2693474/pubmed" id="2693474" target="_blank">2693474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16498259">
<a name="16498259"></a>Castelli F, Saleri N, Tomasoni LR, Carosi G. Prevention and treatment of traveler's diarrhea. Focus on antimicrobial agents. <i>Digestion</i>. 2006;73 (Suppl 1):109-118. doi:10.1159/000089786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/16498259/pubmed" id="16498259" target="_blank">16498259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2020">
<a name="CDC.2020"></a>Centers for Disease Control and Prevention (CDC). The pre-travel consultation: travelers' diarrhea. The Yellow Book: CDC health information for international travel, 2020. <a href="https://wwwnc.cdc.gov/travel/yellowbook/2020/preparing-international-travelers/travelers-diarrhea" target="_blank">https://wwwnc.cdc.gov/travel/yellowbook/2020/preparing-international-travelers/travelers-diarrhea</a>. Updated November 22, 2019. Accessed March 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28071659">
<a name="28071659"></a>Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2017;112(2):212-239. doi:10.1038/ajg.2016.563<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/28071659/pubmed" id="28071659" target="_blank">28071659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17608775">
<a name="17608775"></a>Chey WD, Wong B. American College of Gastroenterology Guideline on the Management of <i>Helicobacter pylori</i> Infection. <i>Am J Gastroenterol</i>. 2007;102(8):1808-1825.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/17608775/pubmed" id="17608775" target="_blank">17608775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3183851">
<a name="3183851"></a>Drumm B, Sherman P, Karmali M, et al. Treatment of <i>Campylobacter pylori</i>-Associated Antral Gastritis in Children With Bismuth Subsalicylate and Ampicillin. <i>J Pediatr</i>. 1988;113(5):908-912.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/3183851/pubmed" id="3183851" target="_blank">3183851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.1">
<a name="expert.1"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Saunders Elsevier; 2007:2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7851056">
<a name="7851056"></a>Gladziwa U, Koltz U. Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure. <i>Clin Pharmacokinet</i>. 1994;27(5):393-408. doi:10.2165/00003088-199427050-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/7851056/pubmed" id="7851056" target="_blank">7851056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3901731">
<a name="3901731"></a>Gryboski JD, Hillemeier AC, Grill B, Kocoshis S. Bismuth subsalicylate in the treatment of chronic diarrhea of childhood. <i>Am J Gastroenterol</i>. 1985;80(11):871-876.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/3901731/pubmed" id="3901731" target="_blank">3901731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2305176">
<a name="2305176"></a>Gryboski JD, Kocoshis S. Effect of bismuth subsalicylate on chronic diarrhea in childhood: a preliminary report. <i>Rev Infect Dis</i>. 1990;12(suppl 1):S36-S40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/2305176/pubmed" id="2305176" target="_blank">2305176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Casper.1">
<a name="Casper.1"></a>Helidac Therapy (bismuth subsalicylate/metronidazole/tetracycline hydrochloride) East Brunswick, NJ: Casper Pharma; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4545567">
<a name="4545567"></a>Ingestion of bismuth-containing ointment by a breast-fed infant. <i>Mt Sinai J Med.</i> 1974:41(3):498-501.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/4545567/pubmed" id="4545567" target="_blank">4545567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8320625">
<a name="8320625"></a>Israel DM, Hassall E. Treatment and long-term follow-up of Helicobacter pylori-associated duodenal ulcer disease in children. <i>J Pediatr</i>. 1993;123(1):53-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/8320625/pubmed" id="8320625" target="_blank">8320625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28541262">
<a name="28541262"></a>Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). <i>J Pediatr Gastroenterol Nutr</i>. 2017;64(6):991-1003. doi:10.1097/MPG.0000000000001594<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/28541262/pubmed" id="28541262" target="_blank">28541262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khim.1">
<a name="Khim.1"></a>Khim LL; Yi TW. A case report of an end-stage renal failure patient with peptic ulcer disease. <i>SFP.</i> 2017;43(3): 51-54. https://www.cfps.org.sg/publications/the-singapore-family-physician/article/1135_pdf. Accessed September 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31084597">
<a name="31084597"></a>Leung AKC, Leung AAM, Wong AHC, Hon KL. Travelers' diarrhea: a clinical review. <i>Recent Pat Inflamm Allergy Drug Discov</i>. 2019;13(1):38-48. doi:10.2174/1872213X13666190514105054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/31084597/pubmed" id="31084597" target="_blank">31084597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2980389">
<a name="2980389"></a>Lione A. Nonprescription Drugs as a Source of Aluminum, Bismuth, and Iodine During Pregnancy. <i>Reprod Toxicol</i>. 1987-1988;1(4):243-252.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/2980389/pubmed" id="2980389" target="_blank">2980389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12028127">
<a name="12028127"></a>More D, Whisman B, Johns J, Hagan L. Anaphylaxis to Pepto-Bismol. <i>Allergy</i>. 2002;57(6):558. doi:10.1034/j.1398-9995.2002.23703.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/12028127/pubmed" id="12028127" target="_blank">12028127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32579814">
<a name="32579814"></a>Palmer BF, Clegg DJ. Salicylate toxicity. <i>N Engl J Med</i>. 2020;382(26):2544-2555. doi:10.1056/NEJMra2010852<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/32579814/pubmed" id="32579814" target="_blank">32579814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36551397">
<a name="36551397"></a>Pelepenko LE, Janini ACP, Gomes BPFA, de-Jesus-Soares A, Marciano MA. Effects of bismuth exposure on the human kidney-a systematic review. <i>Antibiotics (Basel)</i>. 2022;11(12):1741. doi:10.3390/antibiotics11121741<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/36551397/pubmed" id="36551397" target="_blank">36551397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pepto-Bismol.1">
<a name="Pepto-Bismol.1"></a>Pepto-Bismol (bismuth subsalicylate) suspension [prescribing information]. Cincinnati, OH: Procter &amp; Gamble; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pepto-Bismol.2">
<a name="Pepto-Bismol.2"></a>Pepto-Bismol Chews (bismuth subsalicylate) [prescribing information]. Cincinnati, OH: Procter &amp; Gamble; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pepto-Bismol.3">
<a name="Pepto-Bismol.3"></a>Pepto-Bismol Diarrhea Liquicaps (bismuth subsalicylate) [prescribing information]. Cincinnati, OH: Procter &amp; Gamble; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pepto-Bismol.4">
<a name="Pepto-Bismol.4"></a>Pepto-Bismol Liquid Ultra (bismuth subsalicylate) [prescribing information]. Cincinnati, OH: Procter &amp; Gamble; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27068718">
<a name="27068718"></a>Riddle MS, DuPont HL, Connor BA. ACG Clinical Guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. <i>Am J Gastroenterol</i>. 2016;111(5):602-622. doi:10.1038/ajg.2016.126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/27068718/pubmed" id="27068718" target="_blank">27068718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Soriano-Brucher.1">
<a name="Soriano-Brucher.1"></a>Soriano-Brucher HE, Avendano P, O'Ryan M, et al. Use of Bismuth Subsalicylate in Acute Diarrhea in Children. <i>Rev Infect Dis</i>. 1990;12(suppl 1):51-55.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bismuth-subsalicylate-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 101044 Version 359.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
